China joins WHO-led COVAX for equitable access to Covid-19 vaccines

China said on Friday that it has joined the WHO-led COVAX international initiative which aims to ensure equitable global access to vaccines against the novel coronavirus

Coronavirus, vaccine, covid
File Photo
IANS Beijing
2 min read Last Updated : Oct 09 2020 | 2:56 PM IST

China said on Friday that it has joined the World Health Organization (WHO)-led COVAX international initiative which aims to ensure equitable global access to vaccines against the novel coronavirus.

China said it joined the global initiative to make its vaccines a global good and make them available to developing countries on a priority.

"Even when China is leading the world with several vaccines in advanced stages of R&D and with ample production capacity, it still decided to join COVAX," said China's Foreign Ministry spokesperson Hua Chunying.

"To that end, we have solemnly pledged to make #vaccines developed and deployed by China a global public good, which will be provided to developing countries as a priority, she said.

COVAX has been created to maximise the chances of successfully developing COVID-19 vaccines and manufacture them in the quantities needed to end this crisis.

Coordinated by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI) and the WHO, COVAX aims to have two billion doses of Covid-19 available by the end of 2021, which should be enough to protect high risk and vulnerable people, as well as frontline healthcare workers.

"China will also strengthen vaccine cooperation with relevant countries through the COVAX network," the Chinese Foreign Ministry spokesperson said.

China joining the network will be huge boost to the initiative as the US had earlier said it would not participate in the scheme.

Along with US and Russia, China was absent from list of 156 countries that signed up by September 18 deadline to join the COVID-19 vaccine allocation plan, South China Morning Post reported.

--IANS

gb/in

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineChina

First Published: Oct 09 2020 | 2:54 PM IST

Next Story